ARCA biopharma, Inc. Banner Image

ARCA biopharma, Inc. has reached its limit for free report views

Work for ARCA biopharma, Inc.? Upgrade Your Profile and unlock all your annual reports.

ARCA biopharma, Inc.

  • Ticker ABIO
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
ARCA biopharma, Inc. Logo Image
  • 11-50 Employees
  • Based in Westminster, Colorado
ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA’s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) isMore being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that they believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF.
ARCA biopharma, Inc.

Most Recent Annual Report

ARCA biopharma, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. ARCA biopharma, Inc. has reached its limit for free report views.

Older/Archived Annual Reports